ArticleScientific reports2025
Long-term trends and future projections of liver cancer burden in China from 1990 to 2030.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Persistent and widening geographic disparities in liver cancer mortality in China, 1987-2021: a 35-year analysis from a national perspective.Journal of the National Cancer Center · 2026Article
- Preoperative ⁶⁸Ga-FAPI-04 PET/CT-derived liver fibrosis quantification independently predicts post-hepatectomy liver failure: a histologically validated study.European journal of nuclear medicine and molecular imaging · 2026Article
- Global burden of liver cancer from 1990 to 2021 and 20-year projections: findings from the global burden of disease study 2021.International journal of surgery (London, England) · 2026Article
- Evaluation of metabolite biomarker candidates in detecting HCC in patients with liver cirrhosis.Metabolomics : Official journal of the Metabolomic Society · 2026Article
- Enhancement of the Anti-Hepatoma Activity of Acacetin Through Salt Formation of Sodium Acacetin.Chemistry & biodiversity · 2026Article
- From Synthesis to Mechanism: Biological Evaluation of a p-Toluidine-Based Thiazolidinone-Quinoline VEGFR-2 Candidate Supported by CADD.International journal of molecular sciences · 2026Article
- A Non-Invasive Integrated Model for Accurate Preoperative Identification of the Aggressive Macrotrabecular-Massive Subtype of Hepatocellular Carcinoma: A Single-Center Retrospective Study.Diagnostics (Basel, Switzerland) · 2026Article
- Hepatocellular carcinoma and vitamin D metabolism: novel targets and therapeutic strategies.Cellular oncology (Dordrecht, Netherlands) · 2026Review
- Construction of a Prognostic Model Based on Insulin Resistance-Related Genes to Predict TACE Response and Identification of PD-98059 as a Potential Therapeutic Agent.Journal of hepatocellular carcinoma · 2026Article
- Artificial Intelligence and Radiomics in Primary Liver Cancer Imaging: A Bibliometric and Visualized Analysis.Journal of hepatocellular carcinoma · 2026Article
- Global Cancer Imaging Access: Addressing Barriers and Harnessing Innovations.Radiology. Imaging cancer · 2025Review
- From Large-Scale Characterization to Subgroup-Specific Predictive Modeling: A Study on the Diagnostic Value of Liver Stiffness Measurements in Focal Liver Lesions.Diagnostics (Basel, Switzerland) · 2025Article
- Trends and projections of gallbladder and biliary tract cancer in China: a comprehensive analysis from 1990 to 2030 based on the Global Burden of Disease Study 2021.BMC public health · 2025Article
- Temporal trends and demographic influences on protein-energy malnutrition in China: a comprehensive analysis from 1990 to 2021.Frontiers in nutrition · 2025Article
- Rising burden of pancreatic cancer in China: Trends, drivers, and future projections.PloS one · 2025Article
- Impact of high fasting plasma glucose on liver cancer burden in China: a comprehensive analysis of trends from 1990 to 2021.Frontiers in nutrition · 2025Article
- Knowledge, Attitudes, and Practices Regarding Hepatitis B and Liver Cancer Among Liver Cancer Patients and Their Families in China.Cancer management and research · 2025Article
- Burden of colorectal cancer attributable to dietary risks in China from 1990 to 2021: findings from the Global Burden of Disease Study 2021.Frontiers in nutrition · 2025Article
- Burden and trends of cancer attributable to occupational asbestos exposure in China from 1990 to 2021.Frontiers in public health · 2025Article
- Long-term trends in the burden of cancer attributable to high body mass index in China from 1990 to 2021.Frontiers in nutrition · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Liver cancer remains a significant public health issue in China, exhibiting high incidence, mortality, and burden. Understanding its temporal trends and projections is essential for designing targeted prevention and treatment strategies. This study analyzes long-term trends in liver cancer incidence, prevalence, mortality, and burden from 1990 to 2021, assessing age, period, and cohort effects, and projecting future trends. Data on liver cancer incidence, prevalence, mortality, disability-adjusted life years (DALYs), years lived with disability (YLDs), and years of life lost (YLLs) were analyzed from 1990 to 2021. Joinpoint regression analysis, age-period-cohort (APC) analysis, and BAPC modeling were applied to examine trends and project future trends. Decomposition analysis examined contributions of aging, epidemiological changes, and population growth. The study also compared China's liver cancer trends with global data. From 1990 to 2021, China experienced a decrease in age-standardized rates for liver cancer incidence, prevalence, mortality, and burden. Notably, Age-standardized incidence rates (ASIR) exhibited a decline after 2016, with a significant reduction in the male population. In 2021, there were 196,637 new cases of liver cancer in China, with a higher burden in males. ASIR were 14.34 per 100,000 for males and 4.89 per 100,000 for females. Mortality also followed a declining trend, with a notable decrease in age-standardized mortality rates. The age-standardized mortality rate (ASMR) for males was 12.4 per 100,000, significantly higher than for females (4.57 per 100,000) in 2021. Additionally, the age-standardized prevalence rate (ASPR) was 20.0 for males and 6.64 for females, with 265,539 total cases. The burden, measured by DALYs, YLDs, and YLLs, also showed a notable decline in age-standardized rates and significant gender disparities. Despite this, the absolute number of cases, deaths, and DALYs has continued to rise due to population growth and aging, with males bearing a significantly higher burden than females. The study also highlights the impact of aging, population growth, and epidemiological changes on liver cancer incidence and mortality in China. Projections for 2030 suggest a continued decrease in liver cancer incidence, especially among females, reflecting the effectiveness of public health interventions and medical advancements. However, gender disparities remain significant, and further efforts are needed to reduce the overall liver cancer burden, with an emphasis on early detection and prevention strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.